Advertisement Eli Lilly, HCL to establish Co-Innovation Lab in Singapore - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Eli Lilly, HCL to establish Co-Innovation Lab in Singapore

Eli Lilly and HCL Technologies have joined hands to establish a Co-Innovation Lab in Singapore and aims to develop new technologies and improve operational efficiencies of the pharma firm.

The new facility will be made in 35000sqft area HCL’s Jurong Development Center in Singapore and is expected to be run under collaborations with educational and academic research centers.

Under the agreement, both the parties will keep on tracking technology trends and will create Proof of Concept (PoCs) for applied solution frameworks.

HCL will enhance its automation, cloud computing, enterprise mobility and business analytics segments, and will provide support to Eli Lilly in its global operations.

Eli Lilly vice president and chief information officer Michael Heim said they are delighted to launch this Co-Innovation Lab with HCL which will serve as a center for their company’s efforts to leverage IT to create competitive differentiators for their business.